Guardant Health Inc.
FDA Advisory Committee Strongly Recommends Approval of Guardant Health's Shield Blood Test for Colorectal Cancer Screening
Summary
On May 23, 2024, Guardant Health, Inc. announced that the FDA Advisory Committee strongly recommended approval of its Shield blood test for colorectal cancer screening in adults aged 45 and older at average risk. The advisory panel voted favorably on the test's safety, effectiveness, and the benefits outweighing the risks. This recommendation is a significant step towards potential FDA approval and could increase screening rates, addressing a critical gap in current non-invasive screening options.
Profitelligence Alerts
Get alerts for GH
Be first to know when Guardant Health Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Guardant Health Inc.
Guardant Health Inc. is an innovative biotechnology company specializing in the development and commercialization of precision oncology diagnostics. This company is recognized for its groundbreaking work in non-invasive cancer detection through liquid biopsy technologies, which involve analyzing circulating tumor DNA in blood samples. Guardant Health’s primary function is to provide oncologists and researchers with critical tools and data to better understand cancer, tailor treatments, and monitor disease progression, potentially improving patient outcomes significantly. Guardant Health operates prominently in the healthcare and biotechnology sector, significantly impacting fields such as cancer research and personalized medicine. Their products and services are vital for facilitating early detection of cancer, identifying treatment options, and offering companion diagnostics for pharmaceutical developments. In the financial market, Guardant Health represents an important player within the precision medicine landscape, influencing investment within the biotechnology and healthcare sectors. Founded in 2012 and headquartered in Redwood City, California, the company continues to expand its portfolio and advance its technologies, playing a pivotal role in the fight against cancer at a global level.
Official SEC Documents
Advertisement